© 2023 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
The North American Menopause Society (NAMS) has announced the release of a new position statement outlining the organization’s stance on hormone therapy.
Published on July 7, the statement was published with the intent of providing clinicians and patients with an update to the organization’s 2017 position statement on the same topic and has been endorsed by more than 20 international organizations, including the American Association of Clinical Endocrinology and the American Medical Women’s Association.
"NAMS is pleased to announce the release of its updated Position Statement on hormone therapy," says Stephanie S. Faubion, MD, NAMS Medical Director and lead of the Position Statement Advisory Panel, in a statement from NAMS. "Since our last Position Statement on hormone therapy published in 2017, there have been important additions that further clarify the balance of risks and benefits of hormone therapy options for menopause symptoms. NAMS has reviewed existing data on hormone therapies published after the last Position Statement and, after exhaustive research and review of the literature, we have found that what hasn't changed is that hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture."
The 28-page document, which cites more than 340 references, was composed by Faubion, along with an advisory panel of 13 additional experts and was approved by the NAMS board of trustees. Using data from the review used to formulate the 2017 position statement and a more recent assessment of evidence, the position statement emphasizes the role of hormone therapy as the most effective treatment for vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM). In the aforementioned release, NAMS provided selected highlights from the new position statement.
Highlights from 2022 Hormone Therapy Position Statement of NAMS:
This statement, “The 2022 hormone therapy position statement of The North American Menopause Society,” was published in Menopause.